US2004220090A1PendingUtilityA1
Advanced glycation end-product intermediaries and post-amadori inhibition
Assignee: KANSAS UNIVERSITY MEDICAL CTPriority: Sep 12, 1995Filed: Apr 28, 2004Published: Nov 4, 2004
Est. expirySep 12, 2015(expired)· nominal 20-yr term from priority
G01N 33/6842A61K 31/00A61K 31/04A61K 31/435A61K 31/44A61K 31/4415A61K 31/506A61K 31/675A61K 38/05A61K 38/06A61K 38/07C07K 5/06034C07K 5/06052C07K 5/0812G01N 33/68G01N 2400/02G01N 2500/04
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
Claims
exact text as granted — not AI-modified1 - 19 . (Canceled).
20 . A method for treating one or more disorders selected from the group consisting of nephropathy, proteinuria, albuminuria, impaired glomerular clearance, impaired creatinine clearance, retinopathy, and neurodegenerative disease, comprising administering to a subject with one or more of the disorders an amount effective of pyridoxamine to treat the disorder.
21 . The method of claim 20 wherein the subject is a diabetic subject.
22 . The method of claim 21 wherein the one or more disorders comprises nephropathy.
23 . The method of claim 21 wherein the one or more disorders comprises proteinuria.
24 . The method of claim 21 wherein the one or more disorders comprises albuminuria.
25 . The method of claim 21 wherein the one or more disorders comprises impaired glomerular clearance.
26 . The method of claim 21 wherein the one or more disorders comprises impaired creatinine clearance.
27 . The method of claim 21 wherein the one or more disorders retinopathy.
28 . The method of claim 21 wherein the one or more disorders comprises neurodegenerative disease.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.